SCHEMBL4933822

SCHEMBL4933822

COC(=O)c1nscc1NC(=O)c1c(Cl)cccc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.57
MEN1 O00255 5/20 0.57
POLB P06746 2/20 0.57
ABL1 P00519 1/20 0.44
SRC P12931 1/20 0.44
TYK2 P29597 6/20 0.43
JAK2 O60674 4/20 0.43
JAK1 P23458 4/20 0.43
CYP3A4 P08684 1/20 0.43
RAB9A P51151 1/20 0.42
CRHBP P24387 1/20 0.41
HTT P42858 1/20 0.41
CRHR2 Q13324 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
TAS1R2 Q8TE23 1/20 0.40
GHSR Q92847 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4924390 0.85 KMT2A (0.55) KMT2AMEN1POLBTYK2JAK2
SCHEMBL4898095 0.84 POLB (0.47) KMT2AMEN1POLBTYK2JAK2
SCHEMBL3607746 0.82 KMT2A (0.60) KMT2AMEN1POLBRAB9AHTT
SCHEMBL1070972 0.77 KMT2A (0.55) KMT2AMEN1POLBABL1SRC
SCHEMBL14114409 0.75 CDK5 (0.47) ALDH1A1
SCHEMBL27912113 0.73 NPSR1 (0.45) POLBSMN1; SMN2MAPTALDH1A1GAA
SCHEMBL4936632 0.72 CDK14 (0.46) RAB9A
SCHEMBL4924406 0.71 HSPA5 (0.40) KMT2AMEN1POLBRAB9ASMN1; SMN2
SCHEMBL19554514 0.71 KMT2A (0.40) KMT2AMEN1HTTMAPTALDH1A1
SCHEMBL14114411 0.70 MT-CO2 (0.52) KMT2AMEN1TYK2JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US disclosed
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US disclosed
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US disclosed
EP-1781647-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP disclosed
WO-2006008545-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167309-A1 Pharmaceutical Compounds CCNO, CDK2, CDK1 KMT2A 775/4885MEN1 1071/4885POLB 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.